Pomerantz Law Firm Investigates Claims On Behalf of Investors of Boston Scientific Corporation - BSX

Pomerantz LLP is investigating potential securities fraud claims against Boston Scientific Corporation (BSX) following a significant drop in its stock price. This investigation stems from the company’s release of fourth-quarter 2025 financial results, which showed lower-than-expected sales in its electrophysiology division. On February 4, 2026, Boston Scientific’s stock fell by $16.12 per share, or 17.6%, closing at $75.50.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)